AdAlta has announced a strategic collaboration with Oktopi to access its software-as-a-service knowledge system, designed to sharpen decisions in medicine development.

OncoSil Medical has been chosen to join PALACROS, a major European academic consortium aimed at improving outcomes for patients with unresectable locally advanced pancreatic cancer.

Starpharma has reported encouraging preclinical results for its DEP HER2-targeted radiotherapy candidate, DEP HER2 Lu, paving the way for a planned first-in-human Phase 1 study in the second half of 2026.

Neuren CEO Jon Pilcher said, “I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU in the EU."

Chief Executive Officer James Graham said, "The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company, and ahead of interim data readouts in Indonesia, which is a positive step towards the potential commercialisation of R327G."

The company said the funds will underwrite ongoing investment in the development and commercialisation of its blood-based early cancer detection portfolio and support planned activities through 2027.

Dr Bill Mezzanotte, CSL’s Head of Research and Development, said, “While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full."

Algorae Pharmaceuticals has been announced as a founding participant and the healthcare and life sciences launch partner for the Sovereign AI Infrastructure initiative, led by AgenticScale.ai and built on NVIDIA-accelerated technology.

Avecho Biotechnology has moved a major step closer to completing its pivotal Phase 3 study of a TPM-enhanced cannabidiol capsule for insomnia after an independent Data Monitoring Board unanimously recommended that the trial continue with its originally planned enrolment of 519 participants.

INOVIQ says the findings reinforce the broader potential of its off-the-shelf cell-free CAR exosome platform, which has now shown activity in triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer.

AFT Pharmaceuticals has announced that the US Food and Drug Administration has reviewed and allowed the company’s Investigational New Drug application for its injectable iron project to proceed to a global Phase 3 clinical trial.

Neurizon Therapeutics this week disclosed new preclinical data for its lead ALS candidate, NUZ-001, that the company will present at the BIO International Convention 2026.

The company presented the findings at the International Mental Health Conference on the Gold Coast and described clinically significant reductions in depression and trauma symptoms alongside improvements in quality of life and daily functioning.

MTPConnect has adopted a new name as it enters its second decade, rebranding itself as AUScelerate. The organisation said the change aims to better reflect its mission to commercialise Australian life sciences.

UniQuest and the Ellison Medical Institute have signed an exclusive licence that could push a promising University of Queensland treatment for advanced prostate cancer into first-in-human trials as early as 2027.

Recce Pharmaceuticals has received approval from the Human Research Ethics Committee to advance its Australian study of RECCE 327 Topical Gel to a pivotal Phase 3 trial for diabetic foot infections, a move the company says accelerates its global registration strategy.

Invion has taken a step to strengthen its clinical leadership by appointing Dr Colin Hopper, a globally recognised authority in photodynamic therapy, as a clinical advisor.